(Reuters) Israeli biotech company Bonus Biogroup's lab-grown, semi-liquid bone graft was successfully injected into the jaws of 11 people to repair bone loss in an early stage clinical trial, it said on Monday. The material, grown in a lab from each patient's own fat cells, was injected into the voids of the problematic bones. Over a few months it hardened and merged with the existing bone to complete the jaw. "For the first time worldwide, reconstruction of deficient or damaged bone tissue is achievable by growing viable human bone graft in a laboratory, and transplanting it back to the patient in a minimally invasive surgery via injection," said chief executive Shai Meretzki.
2016-12-09 00:00:00Full ArticleBACK Visit the Daily Alert Archive